pharmaphorum

FEBRUARY 22, 2022

A study has suggested people with epilepsy may show patterns of activity and behaviour on social media that could serve as an early warning signal for sudden death – a rare but much feared complication of the disease. The study was carried out in six individuals who suffered sudden unexpected death in epilepsy (SUDEP), with the researchers analysing hundreds of Facebook posts for each subject in the six months leading up to their death, with the consent of surviving family members.

115

115

Roots Analysis

FEBRUARY 22, 2022

With the increasing global population, the incidence rates of several chronic disease indications, such as diabetes, anaphylaxis, rheumatoid arthritis and psoriasis, are on the rise. This has led to a rise in the demand for effective treatment options for patients suffering from these diseases. Further, in order to improve the quality of life in these patients, companies have developed novel devices capable of delivering a variety of formulations of different drugs / therapies, in an efficient a

Dosage 52

Dosage Immunization FDA 52

pharmaphorum

FEBRUARY 22, 2022

A study has revealed that current NHS guidelines on testing for genetic alterations linked to cancer could be missing around half of people carrying them, says a new study. The work by scientists at the Institute for Cancer Research (ICR) suggests that access to genetic testing should be made easier because the guidelines as drawn up “would have excluded many people who had ‘actionable’ genetic alterations that could raise their risk of cancer.” Cancer is not usually inhe

105

105

Outsourcing Pharma

FEBRUARY 22, 2022

A representative from the HIV-centered pharmaceutical company shares thoughts and perspective on the every-two-month treatment and how it might help patients.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA 52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

FEBRUARY 22, 2022

A virtual menopause clinic service developed by Bia Care is starting a randomised clinical trial within the NHS that will not only test how well it performs, but also attempt to tackle inequalities in women’s health. The trial has been announced shortly after Bia Care was awarded additional funding from the NHS to extend the rollout of its digital platform, which helps women book an appointment, have a group online consultation with a doctor, get a personalised plan for managing menopause

104

104

Outsourcing Pharma

FEBRUARY 22, 2022

The agency has given the go-ahead for a Phase I study of the companyâs IO-202 antibody (in combination with Merckâs Keytruda) to treat various tumor types.

Immunization 52

Immunization FDA 52

Pharma Times

FEBRUARY 22, 2022

The European Commission finds that Servier committed a breach of competition over blood pressure drug

53

53

pharmaphorum

FEBRUARY 22, 2022

The FDA has approved expanded labelling for Abbott’s CardioMEMS HF System, an implantable sensor that provides an early warning of worsening heart failure, that could make it an option for more than a million more patients. The new approval makes the CardioMEMS device – which was first approved in the US in 2014 – an option for earlier-stage patients, specifically those with New York Heart Association class II heart failure and a blood test that shows elevated levels of the biomarker natri

FDA 64

FDA Labelling 64

Pharma Times

FEBRUARY 22, 2022

Study involving 10,000 patients will investigate a range of potentially ground-breaking oral antivirals

47

47

pharmaphorum

FEBRUARY 22, 2022

UK biotech Synairgen saw the value of its shares crater after its inhaled interferon beta therapy SNG001 was found to provide no benefit to people hospitalised with COVID-19. The drug – originally developed for asthma – missed both primary and secondary efficacy measures in the 623-patient SPRINTER trial , including a failure to reduce the time it took for patients to be discharged from hospital or recover from COVID-19 compared to placebo.

Hospitals 59

Hospitals Vaccines 59

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

FEBRUARY 22, 2022

There’s been hardly any change in the use of clot-dissolving (thrombolytic) therapies for conditions like heart attack and stroke for decades, but a small Dutch biotech – TargED Biopharmaceuticals – is hoping to disrupt the market with a new and improved therapy. It has just raised €39 million ($44 million) in first-round financing to help realise that ambition and take its lead product – called Microlyse – into clinical development.

Compounding 59

Compounding 59